Supernus Pharmaceuticals, Inc..
SUPN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The company's portfolio includes products for the treatment of ADHD, epilepsy, and other neurological and psychiatric disorders...Show More
Better Health for All
-50
Supernus Pharmaceuticals' product Oxtellar XR has a reported adverse event rate of 1 in 500 for suicidal thoughts or actions, which translates to 2,000 per million users.
1
The FDA also issued three complete response letters (2022, 2024) and a refusal-to-file notice (2020) for its Parkinson's disease infusion pump (SPN-830) due to concerns about product quality, manufacturing, risk analysis, and device performance.
2
The company states it respects individual privacy and adheres to applicable data privacy/data protection laws and regulations, including HIPAA and HITECH, and protects individually identifiable information for patients and customers.
3
Supernus's Code of Ethics outlines comprehensive risk disclosures, prohibiting proactive communication of off-label information while allowing Medical Affairs to respond to unsolicited requests.
4
The company's clinical studies are designed and conducted in accordance with applicable laws, regulations, and ethical standards like Good Clinical Practices, with participants giving written informed consent.
5
Supernus sponsored the Busy Philipps ADHD Campaign to promote empathy and compassion for people living with schizophrenia.
6
Fair Money & Economic Opportunity
0
No evidence available to assess Supernus Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
In 2024, the CEO-to-median employee pay ratio was 107:1, with the CEO's total compensation at $17,848,004 and the median employee pay at $166,121.
1
Employee reviews indicate an overall rating of 3.1 out of 5 stars, with 46% of employees recommending working at the company and 87% approving of the CEO.
2
Employee feedback also highlights concerns regarding pay and benefits, management, and work-life balance.
3
Fair Trade & Ethical Sourcing
0
Supernus Pharmaceuticals, Inc. relies on third-party commercial manufacturing organizations (CMOs) located in North America, Europe, and Asia for all manufacturing operations, including raw materials, dosage form product, and packaging.
1
The company has agreements with several CMOs, including Patheon Pharmaceuticals, Inc., Packaging Coordinators, Inc., Aphena Pharma Solutions, Catalent Pharma Solutions, Merz GmbH & Co. KGaA, and Zambon S.p.A.
2
Under its agreement with Merz for MYOBLOC, Supernus has an annual minimum purchase requirement of approximately €3.9 million, with the agreement set to expire in July 2027 unless extended.
3
The provided articles do not contain specific information regarding fair trade certifications, supplier audit frequencies, instances of forced or child labor, supply chain traceability, remediation speed for ethical violations, the inclusion of ethical clauses in supplier contracts, the share of spend on high-risk materials, or the percentage of procurement budget directed to diverse suppliers.
Honest & Fair Business
0
Supernus Pharmaceuticals maintains a Code of Ethics & Business Conduct, which all employees must certify they have read and understood annually.
1
The company has a Compliance Hotline (1-866-822-4512) for reporting violations, which can be used anonymously, and strictly prohibits retaliation against those who report concerns in good faith.
2
The company's anti-corruption policy prohibits all bribes and facilitation payments, regardless of recipient type, and outlines compliance with anti-kickback statutes.
3
Additionally, the company's MDD Subsidiaries entered into a Corporate Integrity Agreement (CIA) in March 2019, which required an annual audit by an Independent Review Organization.
4
The company submitted its final report for the CIA in Q2 2024, with review expected to conclude in H1 2025.
5
Kind to Animals
-50
Supernus Pharmaceuticals conducts animal testing for pre-clinical trials and toxicology studies, including carcinogenicity programs, as stated in company reports.
1
The company is listed on a 'Cruelty Free Investing' list for exploiting animals due to this practice.
2
There is no evidence of a formal policy to reduce or replace animal testing, nor any mention of alternative testing methods being employed by the company.
3
The company uses between 10,000 and 15,000 animals annually for testing, based on the most recent available data from 2023.
No War, No Weapons
0
No evidence was found in the provided articles to assess Supernus Pharmaceuticals, Inc. against any of the Key Performance Indicators for the 'No War, No Weapons' ethical value. The articles focus on the company's general code of conduct
1
, patient resources
2
, mission, values, and product pipeline
3
, without providing specific data points related to arms contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, or any other conflict-related metrics.
4
Planet-Friendly Business
0
No specific data points or relevant information regarding Supernus Pharmaceuticals, Inc.'s environmental performance were found in the provided article to assess against the Planet-Friendly Business KPIs.
1
Respect for Cultures & Communities
0
No evidence available to assess Supernus Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Supernus Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No relevant data was found in the provided articles to assess Supernus Pharmaceuticals, Inc. against the 'Zero Waste & Sustainable Products' ethical value.
1
The articles explicitly state that they do not contain any quantitative data, regulatory actions, certifications, or other information pertinent to the listed metrics.
2